Ambit Biosciences announces drug screening collaborations
Ambit Biosciences, a privately-held biopharmaceutical company, has entered into a kinase screening collaborations with GlaxoSmithKline (GSK) and Bristol-Myers Squibb (B-MS).
Ambit Biosciences, a privately-held biopharmaceutical company, has entered into a kinase screening collaborations with GlaxoSmithKline (GSK) and Bristol-Myers Squibb (B-MS).
Under the collaboration, Ambit will employ its proprietary kinase platform to characterize the specificity of certain Bristol-Myers Squibb compounds.
Ambit's groundbreaking kinase platform is a rapidly expanding panel of more than 170 quantitative, high-throughput kinase assays.
'Our kinase platform enables Ambit and our partners to fundamentally improve and accelerate the process of identifying high-quality, small molecule kinase inhibitors,' said Scott Salka, ceo of Ambit.
Ambit has also entered into an expanded compound profiling collaboration with Pfizer's La Jolla laboratories to employ its proprietary 'reverse screening' technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds, and thereby elucidate their molecular mechanism of action.